We are developing gene therapy product candidates in the retinal, metabolic and neurodegenerative therapeutic areas.
research | preclinical | phase I/II | phase III | Commercial Rights | |
---|---|---|---|---|---|
Wet AMD (subretinal)
ABBV-RGX-314
|
U.S. Equal Profit Share Ex-U.S. Tiered Royalties
|
||||
Wet AMD (suprachoroidal)
ABBV-RGX-314
|
U.S. Equal Profit Share Ex-U.S. Tiered Royalties
|
||||
Diabetic retinopathy (suprachoroidal)
ABBV-RGX-314
|
U.S. Equal Profit Share Ex-U.S. Tiered Royalties
|
||||
Other chronic retinal conditions |
U.S. Equal Profit Share Ex-U.S. Tiered Royalties
|
||||
Batten disease (CLN2)
RGX-381
|
Worldwide |
||||
Duchenne muscular dystrophy
RGX-202
|
Worldwide |
||||
Hunter syndrome (MPS II)
RGX-121
|
Worldwide |
||||
Hurler syndrome (severe MPS I)
RGX-111
|
Worldwide |
||||
Batten disease (CLN2)
RGX-181
|
Worldwide |